Mindset Pharma

Mindset Pharma CEO says the firm's recent efforts in the psychedelic space are delivering

Mindset Pharma to move forward with its psilocybin-based compound named MSP-1014

Mindset Pharma 'excited' by recent, positive findings on its DMT-inspired chemicals

Mindset Pharma | New Patents and a Message to Psychedelic Investors (CSE:MSET)

'Do Shrooms Make You COLD?' w/ Mindset Pharma's CSO Joseph Araujo @ Psychedelic Capital Aug '21

Mindset Pharma develops rodent studies to differentiate between psychedelic and non-psychedelics

Q&A with James Lanthier, CEO of Mindset Pharma (MSET-CSE)

Creating a quality mindset at a global pharma company

Mindset Pharma strengthens IP portfolio with new provisional patent application

Investment Spotlight: Mindset Pharma with James Lanthier

Mindset says new collab with Otsuka is 'first' Big Pharma and psychedelic partnership

Psychedelic Stocks in Focus | Business Update: James Lanthier, CEO of Mindset Pharma

Mindset Pharma inks agreement to begin collaborating with Global Neuroscience Pharmaceutical Giant !

Mindset Pharma say latest results further validate lead candidate's comparison to psilocybin

Greenshoe Minute - Mindset Pharma Inc. (MSET:CSE)

High Growth Stock to Watch | Cheap Biotech Stock | Stock News Today | Mindset Pharma | MSET

Mindset CEO Reveals His Strategy - Trade To Black #12

Mindset adds to IP portfolio with three non-tryptamine families of next-gen psychedelic compounds

Get Your Company Into the Quality Mindset | Pharma Biotech

Psychedelic Therapy: Joseph Araujo, Cofounder & Chief Scientific Officer, Mindset Pharma

Mindset Pharma CEO says it has 'covered an enormous amount of ground' in its fiscal 2021

Mindset Pharma (OTC:MSSTF) Streetlight Equity Review

Mindset Pharma Halftime Report 2022

CSE Welcome Mindset Pharma Inc.-CSE:MSET